Search Results - "Lynce, F."

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study by Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P. R., Nunes, R., Herbolsheimer, P., Warren, R., Srichai, M. B., Hofmeyer, M., Cunningham, A., Timothee, P., Asch, F. M., Shajahan-Haq, A., Tan, M. T., Isaacs, C., Swain, S. M.

“…Purpose HER2-targeted therapies have substantially improved the outcome of patients with breast cancer, however, they can be associated with cardiac toxicity…”
Get full text

16INCombining PARP inhibitors with CPI by Lynce, F

Get full text

Combining PARP inhibitors with CPI by Lynce, F.

Get full text

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer by Bardia, Aditya, Hurvitz, Sara A, Tolaney, Sara M, Loirat, Delphine, Punie, Kevin, Oliveira, Mafalda, Brufsky, Adam, Sardesai, Sagar D, Kalinsky, Kevin, Zelnak, Amelia B, Weaver, Robert, Traina, Tiffany, Dalenc, Florence, Aftimos, Philippe, Lynce, Filipa, Diab, Sami, Cortés, Javier, O’Shaughnessy, Joyce, Diéras, Véronique, Ferrario, Cristiano, Schmid, Peter, Carey, Lisa A, Gianni, Luca, Piccart, Martine J, Loibl, Sibylle, Goldenberg, David M, Hong, Quan, Olivo, Martin S, Itri, Loretta M, Rugo, Hope S

“…Patients with metastatic triple-negative breast cancer were treated with standard chemotherapy or the anti–Trop-2 antibody–drug conjugate sacituzumab…”
Get full text

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study by Morganti, S., Kim, S.E., Jin, Q., Cha, J., Zeigler, J.E., Newman, A.B., Vincuilla, J., Parker, T., Buehler, R., Mittendorf, E.A., King, T.A., Bychkovsky, B., Curigliano, G., Partridge, A.H., Lin, N.U., Garber, J.E., Tayob, N., Tolaney, S.M., Lynce, F.

Get full text

206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications by Tarantino, P., Niman, S.L., Erick, T., Priedigkeit, N., Harrison, B., Giordano, A., Nakhlis, F., Bellon, J.R., Parker, T., Strauss, S., Jin, Q., King, T.A., Overmoyer, B., Curigliano, G., Regan, M., Tolaney, S., Lynce, F.

Get full text

P1578Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function) by Barac, A, Lynce, F, Medvedofsky, D A, Geng, X, Dang, C, Yu, A, Tan, M, Isaacs, C, Swain, S M, Asch, F M

Get full text

177P Oncotype DX breast recurrence score (ODX RS) and gBRCAm in pts with HR+/HER2-negative early breast cancer (eBC) in a retrospective cohort by Lynce, F., Morganti, S., Khan, R.A., Berrocal-Almanza, L., Miranda, M., Luo, L., Xu, X., Partridge, A.H.

Get full text

Abstract PD8-04: Racial differences in the molecular landscape of breast cancer by Lynce, F, Xiu, J, Nunes, MR, Swain, SM, Gatalica, Z, Isaacs, C, Pohlmann, P

“…Abstract Background:African Americans (AA) have a higher mortality associated with breast cancer (BC) when compared to Caucasians (CC).This has been attributed…”
Get full text

Abstract P6-10-05: UPTAKE study - Uptake of preventive surgeries among Latinas with BRCA1/2 mutations by Lynce, F, Serrano, A, Friedman, S, Nahleh, Z, Dutil, J, Campos, C, Ricker, C, Rodriguez, P, Duron, Y, Isaacs, C, Graves, K

“…Abstract Introduction: Germline testing for BRCA1/2 genes provides an opportunity to reduce mortality and morbidity by adopting appropriate risk reduction and…”
Get full text

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study by Vidal, G, Kalinsky, K, Stringer-Reasor, E, Lynce, F, Cole, J, Valdes-Albini, F, Soliman, H, Nikolinakos, P, Silber, A, DeMichele, A, Ali, H, Graham, D, Giguere, J, Brufsky, A, Liang, Y, Holland, S, Fiji, G, O'Keeffe, B, Gogineni, K

“…Abstract Background: CB-839 is an investigational first-in-class, potent, oral inhibitor of glutaminase (GLS), a mitochondrial enzyme that controls a critical…”
Get full text

Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study by Khoury, K, Isaacs, C, Gatti-Mays, ME, Donahue, RN, Schlom, J, Wang, H, Gallagher, C, Graham, D, Warren, R, Dilawari, A, Swain, SM, Pohlmann, PR, Lynce, F

“…Abstract Background: Long-term follow-up of neoadjuvant studies demonstrates poor clinical outcomes in patients with TNBC who do not achieve pathologic…”
Get full text

152P Inflammatory breast cancer (IBC) in low and middle-income countries (LMICs): Knowledge, and practice patterns - The BRIDGES study by Schlam, I.M., Hirko, K., Gerson, D. Shveid, Abuali, I., Sewaralthahab, S., Nakhils, F., Hazra, A., Lengyel, C.G., Altuna, S.C., Hussain, S., Seid, F.U., Nidhamalddin, S.J., Odhiambo, A.O., Leone, J.P., Metzger, O., Chen, W., Curigliano, G., Tolaney, S.M., Lynce, F., Trapani, D.

Get full text

Abstract OT2-01-09: PALINA: A phase II safety study of pal bociclib in combination with letrozole in A frican American women with hormone receptor positive HER2 negative advanced breast cancer by Lynce, F, Shajahan-Haq, A, Cai, L, Graham, D, Gallagher, C, Mohebtash, M, Kamugisha, L, Novielli, N, Castle, J, Forero, A, Isaacs, C

“…Abstract Background:Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) who are known to have a high…”
Get full text

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer by Heeke, Arielle, Nunes, Maria Raquel, Lynce, Filipa

“…Purpose of Review Bone-modifying agents have an important role in the treatment of patients with bone mineral density loss, early-stage breast cancer to reduce…”
Get full text

Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA : (TOPACIO/Keynote-162) by Vinayak, S, Tolaney, SM, Schwartzberg, L, Mita, M, McCann, G, Tan, AR, Wahner Hendrickson, A, Forero, A, Anders, C, Wulf, G, Dillon, P, Lynce, F, Zarwan, C, Erban, J, Färkkilä, A, Zhou, Y, Buerstatte, N, Graham, JR, Arora, S, Dezube, B, Telli, ML

“…Abstract Background: PARP inhibitor (PARPi) monotherapy has previously demonstrated clinical activity only in patients with a germline BRCA mutation (BRCAmut),…”
Get full text

Abstract P2-12-03: BRCA1/2 testing in an urban population of black women (BW) by Lynce, F, Stein, JE, Demarco, T, Isaacs, C, Smith, KL

“…Abstract Background: Current indications for BRCA1/2 testing do not vary by race or ethnicity except for Ashkenazi Jewish individuals. Uptake of BRCA1/2…”
Get full text

Abstract P3-04-01: ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors by Tan, A, Feldman, R, Pohlmann, P, Lynce, F, Swain, S, Nunes, MR, Gatalica, Z, Ghazalpour, A, Swensen, J, Vidal, G, Obeid, E, Vacirca, J, Isaacs, C, Schwartzberg, L

“…Abstract Background: ESR1 mutations and fusions arise in hormone receptor positive (ER+ and/or PR+) breast cancer (HR+ BC) patients after aromatase inhibitor…”
Get full text

Abstract P3-10-02: Increasing participation in research - breast cancer (Inspire-BrC) by Swain, S, Robinson, BN, Newman, AF, Tefera, E, Herbolsheimer, P, Nunes, R, Gallagher, C, Randolph-Jackson, P, Omogbehin, A, Dilawari, A, Pohlmann, P, Mohebtash, M, Ottaviano, Y, Mohapatra, A, Lynce, F, Mete, M

“…Abstract Background: Increasing Black patients' participation in cancer clinical trials is important because of the population's lower survival rate. Accrual…”
Get full text

12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial by Lynce, F., Brasó-Maristany, F., Waks, A.G., Gonzalez, P. Villagrasa, Villacampa, G., Torres, E. Sanfeliu, Galván, P., Brunet, L. Pare, Anderson, L., Perou, C.M., Parker, J., Vivancos, A., Dilullo, M., Simon, S. Pernas, Winer, E.P., Overmoyer, B., Mittendorf, E.A., Prat, A., Tolaney, S.M.

Get full text